In addition, this is not a direct stand-alone Class I or III recommendation in the guidelines and has shortcomings pertinent to measure feasibility and accountability. QM-7 Inpatient Anticoagulant Dosing Protocol This measure is being retired because it covers only one aspect of medication use and misses other aspects such as inappropriate use. In addition, this is not a direct stand-alone Class I or III recommendation in the guidelines and has shortcomings pertinent to measure feasibility and accountability. QM-8 Inpatient Anticoagulant Error Tracking System This measure is being retired because it covers only limited aspects of medication use and misses other aspects such as inappropriate use. In addition, this is not a direct stand-alone Class I or III recommendation in the guidelines. AMI indicates acute myocardial infarction; LDL, low-density lipoprotein; NSTEMI, non ST-elevation myocardial infarction; PM, performance measure; QM, quality measure; and STEMI, ST-elevation myocardial infarction. Table 5. Revised STEMI and NSTEMI Measures # Care Setting Measure Title Rationale for Revision of the Measure PM-4 Inpatient Statin for AMI This measure is being revised to reflect the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults,14 which recommended statin use for all patients with established atherosclerotic cardiovascular disease, including patients with AMI. PM- 5 Inpatient Evaluation of LVEF The title of this measure is being revised from Evaluation of Left Ventricular Systolic Function to Evaluation of Left Ventricular Ejection Fraction. The treatment recommendations regarding the use of guideline-directed medication therapies are based on LVEF, not qualitative estimates of left ventricular systolic function. The 2013 ACCF/AHA STEMI explicitly recommended measuring LVEF. The 2014 AHA/ACC NSTE-ACS guidelines11 likewise have medication recommendations based on knowledge of the ejection fraction. 